Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion

In Russian Federation in 2022, the Expert Council adopted the main definitions and terms for neuromyelitis optica spectrum disorders (NMOSD) and proposed a treatment algorithm for patients with NMOSD with antibodies to aquaporin-4 (AQP4-IgG). The publication is intended to present the results of the work of the Russian Expert Council in September 2024. The experts agreed on clarifications of previously published terminology, new definitions, current issues in the therapy of NMOSD, proposed profiles of patients with NMOSD for ravulizumab and a monitoring plan during treatment with this drug, and agreed on an updated algorithm for prescribing medications that prevent exacerbations in patients with NMOSD with AQP4-IgG aged 18 years and older.

1. Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139-48. doi: 10.14412/2074-2711-2022-6-139-148 (In Russ.)].

2. Kleiter I, Traboulsee A, Palace J, et al. Long-term Efficacy of Satralizumab in AQP4- IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071

3. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi: 10.1002/ana.26626. Epub 2023 Apr 5.

4. Kümpfel T, Giglhuber K, Aktas O, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and longterm management. J Neurol. 2024 Jan;271(1):141-76. doi: 10.1007/s00415-023- 11910-z. Epub 2023 Sep 7. Erratum in: J Neurol. 2024 Jun;271(6):3702-7. doi: 10.1007/s00415-024-12288-2

5. Paul F, Marignier R, Palace J, et al. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023 May 31;10(4):e200124. doi: 10.1212/NXI.0000000000200124

6. Nakashima I, Nakahara J, Yokote H, et al. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther Adv Neurol Disord. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177

7. Nakashima I, Nakahara J, Yasunaga H, et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Mult Scler Relat Disord. 2024 Apr;84:105502. doi: 10.1016/j.msard.2024.105502. Epub 2024 Feb 12.

8. Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.

9. Pandit L, Mustafa S. Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017 May 2;4(4):e351. doi: 10.1212/NXI.0000000000000351

10. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.

11. Carnero Contentti E, Lopez PA, Pettinicchi JP, et al. Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study. J Neurol Sci. 2024 Jul 15;462:123099. doi: 10.1016/j.jns.2024.123099. Epub 2024 Jun 14.

12. Stepanova AD, Evdoshenko EP, Shumilina MV, et al. Validation of Russian-language version of the Expanded Disability Status Scale (EDSS) for patients with multiple sclerosis in the Russian Federation. Mediczinskie tekhnologii. Oczenka i vy`bor = Medical Technologies. Assessment and Choice. 2023;45(1):41-9. doi: 10.17116/medtech20234501141 (In Russ.).

13. Krasnov VS, Prakhova LN, Totolyan NA. Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):69-76. doi: 10.14412/2074-2711-2022-5-69-76 (In Russ.).

14. Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020 Nov 15;348:577387. doi: 10.1016/j.jneuroim.2020.577387. Epub 2020 Sep 8.

15. Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020 Feb;38:101506. doi: 10.1016/j.msard.2019.101506. Epub 2019 Nov 6.

16. Shosha E, Aljarallah SA, Fugham NA, et al. Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2022 Oct;66:104062. doi: 10.1016/j.msard.2022.104062

17. Kleiter I, Gahlen A, Borisow N, et al; Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

18. Kleiter I, Gahlen A, Borisow N, et al; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504

19. Demuth S, Guillaume M, Bourre B, et al; NOMADMUS Study Group. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022 Mar 2;19(1):62. doi: 10.1186/s12974-022-02420-2

20. Sepulveda M, Armangue T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225

21. Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79. doi: 10.1016/j.mayocp.2016.12.014

22. Wang X, Chen X, Zhu C, et al. A multifacet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG. Medicine (Baltimore). 2018 Nov;97(48):e13100. doi: 10.1097/MD.0000000000013100

23. Chu F, Shi M, Liu C, Zhu J. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody? Clin Exp Immunol. 2023 Oct 13;213(3):363-70. doi: 10.1093/cei/uxad053

24. Wu Y, Geraldes R, Jurynczyk M, Palace J. Double-negative neuromyelitis optica spectrum disorder. Mult Scler. 2023 Oct;29(11-12):1353- 62. doi: 10.1177/13524585231199819. Epub 2023 Sep 23.

25. Akaishi T, Nakashima I, Takahashi T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2019 Nov 22;7(1):e640. doi: 10.1212/NXI.0000000000000640

26. Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428. doi: 10.1016/j.msard.2020.102428. Epub 2020 Jul 29. Erratum in: Mult Scler Relat Disord. 2021 Jul;52:103026. doi: 10.1016/j.msard.2021.103026

27. Hemmer B. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica Spektrum-Erkrankungen und MOG-IgG assoziierten Erkrankungen, S2k-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapiein der Neurologie. Available at: www.dgn.org/leitlinien

28. Kumawat BL, Choudhary R, Sharma CM, et al. Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders. Ann Indian Acad Neurol. 2019 Oct-Dec;22(4):389-94. doi: 10.4103/aian.AIAN_365_19. Epub 2019 Oct 25.

29. Lim YM, Pyun SY, Kang BH, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler. 2013 Aug;19(9):1216-8. doi: 10.1177/1352458512471875. Epub 2012 Dec 21.

30. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-51. doi: 10.1136/jnnp-2017-316286. Epub 2017 Oct 13.

31. Qin C, Tao R, Zhang SQ, et al. Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2020 Nov 12;11:585471. doi: 10.3389/fneur.2020.585471

32. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014 Apr;20(4):501-4. doi: 10.1177/1352458513495938. Epub 2013 Aug 28.

33. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007 Sep;13(8):968-74. doi: 10.1177/1352458507077189. Epub 2007 Jul 10.

34. Takai Y, Kuroda H, Misu T, et al. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord. 2021 Apr;49:102750. doi: 10.1016/j.msard.2021.102750. Epub 2021 Jan 22.

35. Clardy SL, Pittock SJ, Aktas O, et al. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. Neurol Ther. 2024 Jun;13(3):535-49. doi: 10.1007/s40120-024-00597-7. Epub2024 May 9. Erratum in: Neurol Ther. 2024 Aug;13(4):1313-4. doi: 10.1007/s40120-024-00638-1

36. Aungsumart S, Youngkong S, Dejthevaporn C, et al. Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. Front Neurol. 2023 Apr 4;14:1166490. doi: 10.3389/fneur.2023.1166490

37. Ortiz S, Pittock SJ, Berthele A, et al. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Front Neurol. 2024 Jan 31;15:1332890. doi: 10.3389/fneur.2024.1332890

38. Briko NI, Namazova-Baranova LS, Koroleva IS, et al. Resolution of the interdisciplinary council experts for prevention of severe infections in patients with genetic disorders of regulation of the complement system, receiving therapy with eculizumab. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention. 2017;16(1):51-4 (In Russ.).

39. Gomez-Cibeira E, Ivanovic-Barbeito Y, Gutierrez-Martinez E, et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology. 2016 Jan 26;86(4):399-400. doi: 10.1212/WNL.0000000000002312. Epub 2015 Dec 30.

40. Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747

41. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. doi: 10.1016/S1474-4422(20)30078-8

42. Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a metaanalysis. BMC Neurol. 2019 Mar 6;19(1):36. doi: 10.1186/s12883-019-1261-2

43. Wingerchuk DM, Zhang I, Kielhorn A, et al. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurol Ther. 2022 Mar;11(1):123-35. doi: 10.1007/s40120-021-00295-8. Epub 2021 Nov 13.